Travere Therapeutics, Inc. (TVTX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II).
Is Travere Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of October 28, 2026, Travere Therapeutics, Inc. (TVTX) trades at $50.84 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Travere Therapeutics, Inc.
Market cap $5B · 52 weeks $27 – $68 (25 % below the high) · P/E no earnings · 2027 expected P/E 16.5× · Dividend none · Next earnings October 29, 2026 · expected EPS $-0.04 · Closing price, Oct 28 · accounts published Aug 4.
- Valuation: P/Sales 4.8× (no earnings).
- Balance sheet: Distress zone (fragile).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 1 of 4 pass
- R&D / Market cap 4.5 %, fails.
- Market cap / Cash 14.1×, fails.
- Total Debt 1.1×, borderline.
- Annual cash burn $0.42, passes.
Against its peers (reference peers) — Travere Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -6.2 %; $4.8B. PTC Therapeutics, Inc. (P/E —; EV/EBITDA 27.8×; ROIC 2.6 %; $5.3B), Arcutis Biotherapeutics, Inc. (P/E 151×; EV/EBITDA 93.5×; ROIC 9.9 %; $4.0B), Ligand Pharmaceuticals Incorporated (P/E 34.1×; EV/EBITDA 23.1×; ROIC 3.9 %; $6.4B).
Profitability
| Return on Equity | -55.79% |
| Return on Invested Capital | -6.19% |
| Return on Assets | -5.44% |
| Gross Margin | 94.41% |
| Operating Margin | -6.84% |
| Net Margin | -7.35% |
Financial Health
| Debt / Equity | 25.16 |
| Current Ratio | 4.05 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.78 |
Price Performance
| 1 month | -15.19% |
| 3 months | -8.96% |
| Year-to-date | +33.16% |
| 1 year | +69.71% |
| 3 years | +652.66% |
| 5 years | +76.61% |
| 10 years | +169.92% |
Related companies: VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of TVTX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks